TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02762617

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intravaginal ring (IVR)
Description: The Placebo IVR is formulated using preformed flexible tubing, comprised of biomedical medical grade hydrophilic, aliphatic polyurethane, and an inner core compartment comprised of sodium chloride. The ring will be inserted by the study clinician and worn for 28 day intervals for a total of 3 months (84 days). The ring will be removed and replaced with a new ring at each 28 day interval.
Study: NCT02736071

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Women will receive oral Tramadol 100mg 2 hours before the procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1
Description: Women will receive an oral placebo similar to Tramadol 2 hours before the procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 2
Description: Women will receive an oral placebo similar to Celecoxib 2 hours before the procedure
Study: NCT04009980

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OMK2 group
Description: topical administration of OMk2 ophthalmic solution for 36 months three times/day
Study: NCT02887768

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epicardial Infarct Repair with CorMatrix-ECM
Description: CorMatrix-ECM-biomaterial will be surgically applied to the epicardial surface of the infarct myocardium at the time of coronary artery bypass surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary Artery Bypass Grafting Surgery
Description: All participants will undergo standard coronary artery bypass grafting surgery to treat coronary artery disease
Study: NCT04009980

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: topical administration of ophthalmic placebo solution for 36 months three times/day
Study: NCT02862093

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Repetitive Transcranial Magnetic Stimulation of the dorsolateral prefrontal cortex

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Repetitive Transcranial Magnetic Stimulation of the dorsolateral prefrontal cortex
Study: NCT00633841

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AFFITOPE AD02
Description: 4 subcutaneous injections of IP in 4-week intervals

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AFFITOPE AD02
Description: 4 subcutaneous injections of IP in 4-week intervals
Study: NCT02427698

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cyrolipolysis (CoolSculpting device)
Description: Treatment will be a cold exposure for up to 120 minutes using the CoolSculpting device with a commercially available treatment setting.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cyrolipolysis (CoolSculpting device)
Description: Treatment will be a cold exposure for up to 120 minutes using the CoolSculpting device with a commercially available treatment setting.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: subcision
Description: The skin will be punctured using a subcision needle to cut the septa responsible for the skin depression after cryolipolysis.
Study: NCT04810793

Intervention type: DRUG
Intervention: Amoxicillin , Levofloxacin and Esomeprazole
Description: Esomeprazole-Bismuth-Amoxicillin-Levofloxacin-containing quadruple regimens

Intervention type: DRUG
Intervention: Amoxicillin , Furazolidone and Esomeprazole
Description: Esomeprazole-Bismuth-Amoxicillin-Furazolidone-containing quadruple regimens

Intervention type: DRUG
Intervention: Tetracycline , Furazolidone and Esomeprazole
Description: Esomeprazole-Bismuth-Tetracycline-Furazolidone-containing quadruple regimens

Intervention type: DRUG
Intervention: Amoxicillin,Levofloxacin and Vonoprazan fumarate
Description: Amoxicillin-Levofloxacin-Vonoprazan fumarate-containing quadruple group

Intervention type: DRUG
Intervention: Amoxicillin,Furazolidone and Vonoprazan fumarate
Description: Amoxicillin-Furazolidone-Vonoprazan fumarate-containing quadruple group

Intervention type: DRUG
Intervention: Tetracycline,Furazolidone and Vonoprazan fumarate
Description: Tetracycline-Furazolidone-Vonoprazan fumarate-containing quadruple group
Study: NCT00751075

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mometasone furoate nasal spray (MFNS)
Description: Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril once daily in the morning and placebo nasal spray once daily in the evening for 15 days, followed by 14-day no-treatment observation period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MFNS
Description: Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril twice daily for 15 days followed by 14-day no-treatment observation period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Amoxicillin 500 mg/capsule, one capsule 3 times a day for 10 days and placebo nasal spray twice daily for 15 days, followed by a 14-day no-treatment observation period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule three times daily for 10 days and placebo nasal spray twice daily for 15 days, followed by 14-day no-treatment observation
Study: NCT01104415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Description: Telotristat etiprate capsules orally three times daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Description: Telotristat etiprate capsules orally three times daily.
Study: NCT03608839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreous Dexamethasone Solution 4mg/ml - vol 0,01 ml
Description: 0,01 ml intravitreous dexamethasone solution 4mg/ml injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreous Dexamethasone Solution 4mg/ml - vol 0,03 ml
Description: 0,03 ml intravitreous dexamethasone solution 4mg/ml injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreous Dexamethasone Solution 4mg/ml - vol 0,05 ml
Description: 0,05 ml intravitreous dexamethasone solution 4mg/ml injection.
Study: NCT00903266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Melodic Intonation Therapy
Description: MIT emphasizes the prosody of speech through the use of slow, pitched vocalization (singing).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speech-Repetition-Therapy
Description: Speech-Reception-Therapy is an equally intensive, alternative verbal treatment method developed for this study.
Study: NCT02271971

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: A daily 5.000 IU vitamin D3 capsule during 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A daily placebo capsule during 6 weeks.
Study: NCT01794936

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VTI Probe
Description: The VTI 20 MHz microvascular Laparoscopic Doppler System is a blood flow detector that compensates for the loss of tactile sensation during laparoscopic procedures by eliminating misunderstandings related to surrounding vascular anatomy. The system's sterile doppler probes fit through standard 5mm ports, making it easy to use with no special training required.
Study: NCT04043364

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LIVE
Description: Learning, Innovation, Volunteers and Empowerment
Study: NCT03213249

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Intraoperative pocket irrigation with normal saline

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Intraoperative pocket irrigation with normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: Cefazolin, gentamicin, and bacitracin will be mixed together in 1 L of normal saline and placed in the pocket created by the breast once it is removed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin biopsy
Description: Biopsies will be taken from the skin at the time of mastectomy and at the time of implant exchange.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin biopsy
Description: Biopsies will be taken from the skin at the time of mastectomy and at the time of implant exchange.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral skin- or nipple-sparing mastectomies
Description: Standard of care

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral skin- or nipple-sparing mastectomies
Description: Standard of care

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tissue expander
Description: Standard of care

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tissue expander
Description: Standard of care

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Breast implant
Description: * Standard of care~* Either breast implant or autologous flap

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Breast implant
Description: * Standard of care~* Either breast implant or autologous flap

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous flap
Description: * Standard of care~* Either breast implant or autologous flap

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous flap
Description: * Standard of care~* Either breast implant or autologous flap

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acellular dermal matrix sling
Description: Standard of care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acellular dermal matrix sling
Description: Standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin
Description: Cefazolin, gentamicin, and bacitracin will be mixed together in 1 L of normal saline and placed in the pocket created by the breast once it is removed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bacitracin
Description: Cefazolin, gentamicin, and bacitracin will be mixed together in 1 L of normal saline and placed in the pocket created by the breast once it is removed
Study: NCT04300426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACHIM as solute (10^9 intestinal microbes/ml)
Description: Culture of intesinal microbiota originally derived from a healthy subject are administered to a person with presumed dysbiotic intestinal symptoms with an objective to treat these symptoms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ACHIM as solute (10^9 intestinal microbes/ml)
Description: Culture of intesinal microbiota originally derived from a healthy subject are administered to a person with presumed dysbiotic intestinal symptoms with an objective to treat these symptoms.
Study: NCT02737878

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Training
Description: Six months of twice-weekly aerobic training that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of wearables to monitor heart rate. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance.
Study: NCT00638794

Intervention type: DEVICE
Intervention: Drug -Eluting Stent (Taxus™, Cypher®, Endeavor™, Xience V™)
Description: PCI using any FDA approved drug-eluting stent; Taxus Express2 - Paclitaxel-Eluting Coronary Stent System Cypher Sirolimus-eluting coronary stent Endeavor ABT-578 Eluting Coronary Stent System Xience V Everolimus Eluting Coronary Stent System
Study: NCT01418677

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E7389
Description: Severe renal impairment-the dose to be administered will be based on the interim analyses of safety and pharmacokinetics in subjects with moderate renal impairment (Cohort 1).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E7389
Description: Moderate renal impairment-HALAVEN will be dosed at 1.4 mg/m2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E7389
Description: Normal renal function-HALAVEN will be dosed at 1.4 mg/m2.
Study: NCT01221090

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PDA
Description: Technological assistance

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CDSMP
Description: 6-week classes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PDA/CDSMP
Description: Combined technology and education
Study: NCT00962884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory Threshold Device (Res-Q-Gard ITD)
Description: Patient will breathe through this device attached to a mouthpiece during assessment of orthostatic tolerance.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Inspiratory Threshold Device
Description: Breathing through device similar to active device but with the one-way threshold valve removed.
Study: NCT00591435

Intervention type: OTHER
Intervention: Comparison of performance of consultants versus residents
Description: Anesthesia as well as surgical workflow will be analysed. Performance of consultants will be compared to residents

Intervention type: OTHER
Intervention: Comparison of performance of consultants versus residents
Description: Anesthesia as well as surgical workflow will be analysed. Performance of consultants will be compared to residents
Study: NCT00127439

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manually Assisted Locomotor Training
Description: The total program is 45 sessions, 5x/week with total locomotor training (LT) duration of 30 stepping minutes/day. 1) BWS is initiated at 40% and gradually decreasing to 0%, 2) treadmill speed is set at normal walking speeds and increased as tolerated, and 3) manual assistance given when the subject is unable to independently step or control upright posture, and decreased as participant progresses. Trainers assist via verbal cues and manual assistance to achieve good stepping. The goal for endurance is 20 mins of continuous, independent, coordinated stepping on the treadmill at 0% BWS. Participants are encouraged to assist and/or independently maintain an upright posture, weight shift onto the loaded limb, flex or extend their legs, and to swing their arms in coordination with the legs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic Assisted Locomotor Training
Description: The total program is 45 sessions, 5x/week with total locomotor training (LT) duration of 30 stepping minutes/day. 1) BWS is initiated at 40% and gradually decreasing to 0%, 2) treadmill speed is set at normal walking speeds and increased as tolerated, and 3) manual assistance given when the subject is unable to independently step or control upright posture, and decreased as participant progresses. Trainers assist via verbal cues and manual assistance to achieve good stepping. The goal for endurance is 20 mins of continuous, independent, coordinated stepping on the treadmill at 0% BWS. Participants are encouraged to assist and/or independently maintain an upright posture, weight shift onto the loaded limb, flex or extend their legs, and to swing their arms in coordination with the legs.
Study: NCT03817255

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Substance use questionnaire
Description: Questions about substance use based on the Detection of Alcohol and Drug Problems in Adolescents (DEP-ADO) survey.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: Questions about physical activity, based on the short version of the International Physical Activity Questionnaire (IPAQ).
Study: NCT03768531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3 mg/kg will be given intravenously (IV) through a vein in the arm over 30 minutes every 2 weeks. (Cycle length 2 weeks).
Study: NCT00095550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ
Description: Tablets, Oral, Irbesartan 150 mg/HCTZ 12.5 mg, Once daily, 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan monotherapy
Description: Tablets, Oral, 150 mg, Once daily, 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCTZ monotherapy
Description: Tablets, Oral, 12.5 mg, Once daily, 12 weeks.
Study: NCT02737878

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Training
Description: Six months of twice-weekly aerobic training that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of wearables to monitor heart rate. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Six months of twice-weekly resistance training program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of a set of resistance bands of various weights. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Six months of twice-weekly resistance training program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of a set of resistance bands of various weights. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance.
Study: NCT01021722

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified suture technique
Description: Both internal and external anal sphincter was sutured separately end to end
Study: NCT03768531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3 mg/kg will be given intravenously (IV) through a vein in the arm over 30 minutes every 2 weeks. (Cycle length 2 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabrilizumab
Description: Cabiralizumab 4 mg/kg given IV for 30 minutes, 30 minutes after Nivolumab infusion is completed, every 2 weeks. (Cycle length 2 weeks).
Study: NCT03445052

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: XPAND
Description: The intervention is personalised to the psychosocial factors influencing poor photoprotection for each person. These factors could include beliefs that reduce motivation to protect as well as factors that prevent intentions being translated into action. The facilitator will use behaviour change techniques to target the factor most important for each person. Standardised content related to habit formation will be received. The intervention will be delivered via 7 1:1 sessions with a facilitator (psychologists or clinical nurse specialist). Sessions 1 (1.5 hours maximum) and 6 (45 minutes) will be delivered face to face in the home of the participant and the remaining sessions will be conducted via telephone calls or skype sessions.
Study: NCT00591435

Intervention type: OTHER
Intervention: Comparison of performance of consultants versus residents
Description: Anesthesia as well as surgical workflow will be analysed. Performance of consultants will be compared to residents
Study: NCT02857556

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample
Study: NCT00840892

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INTERdisciplinary COMmunity-based COPD management (INTERCOM)
Description: The INTERCOM program consisted of exercise training, education, nutritional therapy and smoking cessation support offered by local physiotherapists and dieticians in the proximity of the patient's home and by respiratory nurses in the hospital. The program was divided in a 4-month intensive intervention phase, followed by a 20-month maintenance phase.
Study: NCT03375359

Intervention type: DIAGNOSTIC_TEST
Intervention: cfDNA screening
Description: cfDNA screening test for aneuploidy risk assessment
Study: NCT04786041

Intervention type: PROCEDURE
Intervention: laparoscopic appendectomy
Description: laparoscopic appendectomy

Intervention type: PROCEDURE
Intervention: laparoscopic appendectomy
Description: laparoscopic appendectomy
Study: NCT02266186

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Cognitive behavioural therapy
Description: Therapist supported live therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet based Cognitive behavioural therapy
Description: Internetbased CBTwith limited therapist support
Study: NCT01508364

Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY 43-9006)
Description: Dosage according to label or at discretion of the attending physician
Study: NCT03487900

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Colonoscopy
Description: Colonoscopy for CD patients in clinical remission
Study: NCT04053452

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral nerve ultrasound
Description: Ultrasound of the bilateral ulnar nerves, median nerves, vagus nerves, and C6 and C7 nerve roots will be performed.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Peripheral nerve ultrasound
Description: Ultrasound of the bilateral ulnar nerves, median nerves, vagus nerves, and C6 and C7 nerve roots will be performed.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Measurement of strength
Description: Strength will be assessed by physical examination and recorded using Medical Research Council (MRC) scale, and a hand dynamometer will be used to measure grip strength.
Study: NCT02857556

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample

Intervention type: OTHER
Group type: OTHER
Intervention: Retinal photography:

Intervention type: OTHER
Group type: OTHER
Intervention: dialyse